Archivos de bronconeumología
-
Arch. Bronconeumol. · Dec 2009
Multicenter Study[Use of indwelling pleural catheter in the outpatient management of recurrent malignant pleural effusion].
To analyse the effectiveness and safety of the indwelling pleural catheter in the management of recurrent malignant pleural effusion. ⋯ The use of an indwelling pleural catheter is an effective palliative treatment in the outpatient management for patients suffering malignant pleural effusion. It is also a simple treatment that can be easily applied, does not require hospitalisation and can be easily managed by the patient at home, with a low rate of complications.
-
Arch. Bronconeumol. · Dec 2009
Multicenter Study[Inflammation markers in the exhaled air of patients with bronchiectasis unassociated with cystic fibrosis].
The aim of the study was to analyse the relationship between the intensity of the respiratory tract inflammation, expressed by oxidative stress markers, and the severity of the disease in patients with bronchiectasis unassociated with cystic fibrosis. ⋯ In our study, the measurement of inflammation markers in exhaled air is only associated with some parameters of severity in patients with bacterial bronchiectasis.
-
Arch. Bronconeumol. · Dec 2009
[Long term effect of autoadjusting positive airway pressure on C-reactive protein and interleukin-6 in men with obstructive sleep apnoea syndrome].
Obstructive sleep apnoea (OSA) has been increasingly linked to cardiovascular disease. Inflammatory processes associated with OSA may contribute to this morbidity. Some studies have reported serum levels of high sensitivity C-reactive protein (hs-CRP) and interleukin-6 (IL-6) to be increased in these patients. ⋯ OSA is associated with a low-grade inflammatory process; hs-CRP serum levels are elevated in OSA patients when comparing to community controls, independently of age and BMI and the former have a significantly higher risk of cardiovascular events when compared to the latter. There was no significant decrease of both inflammatory mediators (hs-CRP, IL-6) after short and long-term APAP therapy.